Core Viewpoint - AAVLINK is a novel gene therapy strategy developed by the Shenzhen Institute of Advanced Technology, which addresses the challenge of efficiently delivering long genes using AAV vectors, potentially advancing clinical applications for neurodevelopmental disorders and other genetic diseases [3][4]. Group 1: Background and Significance - Over 7,000 rare diseases have been identified globally, most of which are caused by genetic mutations and lack effective treatments, posing significant challenges in medicine [3]. - Gene therapy offers new hope for treating rare and hereditary diseases by repairing, replacing, or inhibiting pathogenic genes [3]. Group 2: AAVLINK Methodology - The AAVLINK method innovatively splits long genes into two segments, each packaged in separate AAV vectors; one carries a gene segment with a lox site, while the other carries the second segment and a Cre recombinase gene [4]. - Upon entering cells, the Cre recombinase recognizes the lox sites, allowing for precise reassembly of the split genes, leading to the expression of a full-length functional protein [4]. Group 3: Safety and Efficacy - AAVLINK 2.0 addresses potential issues of gene rearrangement and immune responses, enhancing the safety of clinical applications [4]. - Research indicates that this technology can efficiently reconstruct large gene segments in various cell types without producing truncated proteins, showing significantly higher recombination efficiency compared to traditional methods [4]. - Animal studies demonstrate that AAVLINK can effectively improve behavioral and epileptic phenotypes in relevant mouse models [4]. Group 4: Future Directions - The research team plans to further explore the systemic delivery efficiency of AAVLINK, investigate its mechanisms, and establish disease models, with aims for systematic validation in primate models and preclinical studies to facilitate the technology's translation into clinical practice [4].

Group 1 - The article highlights the publication of seven papers in the prestigious journal Cell, with six authored by Chinese scholars, indicating a significant contribution to the field of scientific research [3]. - AAVLINK, a new strategy for gene therapy, was developed to overcome delivery size limitations, achieving efficient gene recombination and expression of autism-related gene Shank3 and epilepsy-related gene SCN1A in mouse models [5][7]. - The POCKET device, a flexible bioelectronic patch, was created for precise intracellular delivery, demonstrating high delivery efficiency and spatial control in various organs, which could enhance drug delivery and gene transfection [10][12]. Group 2 - A study revealed a novel GPCR-G protein-β-arrestin megacomplex regulated by a versatile allosteric modulator, which could lead to new therapeutic approaches targeting GPCRs, crucial for many clinical drugs [19][21]. - The research on systemic stomatal immunity in plants identified a mobile peptide that transmits danger signals from infected to uninfected leaves, enhancing plant defense mechanisms against pathogens [25][27]. - An innovative urine liquid biopsy method for bladder cancer was developed, improving specificity by removing field effect mutations, which could guide personalized treatment strategies for non-muscle invasive bladder cancer patients [30][32].

Core Insights - The article discusses a novel gene therapy strategy named "AAVLINK," which addresses the challenge of efficiently delivering long genes using AAV (adeno-associated virus) vectors, potentially advancing clinical applications for rare genetic diseases such as autism and epilepsy [1][2]. Group 1: AAVLINK Technology Development - The AAVLINK method allows for the efficient delivery of complete functional genes longer than 11kb by splitting them into two segments, each carried by separate AAVs, which then recombine inside target cells [2][3]. - This technology overcomes the limitations of traditional AAV delivery, which can only transport genes up to 4.7kb, thus expanding the potential for gene therapy in various genetic disorders [2][3]. Group 2: Research and Clinical Implications - The research team demonstrated that AAVLINK can reconstruct and restore the function of genes associated with autism (Shank3) and epilepsy (SCN1A) in animal models, leading to significant behavioral and phenotypic improvements [4][5]. - The team has created a comprehensive tool library for AAV long gene delivery, screening 193 long human pathogenic genes, which includes various diseases such as Duchenne muscular dystrophy and hereditary deafness, facilitating broader applications of the technology [4][5]. Group 3: Future Directions and Clinical Relevance - The AAVLINK platform is now open for use, allowing other research teams to focus on disease mechanisms and treatment optimization, thus enhancing the overall research landscape in gene therapy [5][6]. - The technology is expected to provide innovative solutions for treating difficult-to-manage pediatric epilepsy, addressing the root causes rather than just symptoms, which could significantly improve patient outcomes [6][7].

Core Insights - A research team from the Shenzhen Institute of Advanced Technology has developed a new gene therapy strategy called "AAVLINK," which addresses the challenge of efficiently delivering long genes using AAV (adeno-associated virus) vectors, potentially advancing clinical applications for gene therapies targeting neurological disorders like autism and epilepsy [1][2]. Group 1: Gene Therapy Development - The AAVLINK method innovatively splits long genes into two segments, each carried by separate AAVs, with one AAV containing a special "molecular magic tape" (lox site) and the other carrying the second gene segment along with the Cre recombinase gene [2]. - This approach allows for precise recombination of the split gene segments within target cells, enabling the expression of a complete functional gene [2]. - The technology has been shown to efficiently reconstruct large gene segments in various cell types without producing truncated proteins, demonstrating significantly higher recombination efficiency compared to traditional methods [2]. Group 2: Safety and Future Research - The research team has developed a 2.0 version of the AAVLINK technology that addresses potential issues related to gene rearrangement and immune responses, enhancing the safety of clinical applications [2]. - Animal studies indicate that this technology can effectively improve behavioral and epilepsy phenotypes in relevant mouse models [2]. - Future research will focus on exploring the systemic delivery efficiency of the technology, understanding its mechanisms, establishing disease models, and conducting preclinical studies in primate models to facilitate its practical application [2].